Olema Pharmaceuticals announces participation in upcoming investor conferences focused on its breast cancer therapies and clinical trials.
Quiver AI Summary
Olema Pharmaceuticals, Inc. announced its participation in several upcoming investor conferences, including the TD Cowen 7th Annual Oncology Innovation Summit on May 26, the Jefferies Global Healthcare Conference on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Each event will feature Olema in a fireside chat format, with live webcasts available on the company's investor relations website. Olema is focused on developing targeted therapies for breast cancer, notably advancing its lead candidate, palazestrant, which is in two Phase 3 clinical trials, as well as another candidate, OP-3136, currently in Phase 1. The company is based in San Francisco and operates in Cambridge, Massachusetts.
Potential Positives
- Participation in multiple high-profile investor conferences, showcasing the company's commitment to transparency and investor engagement.
- Advancement of a robust pipeline of novel therapies, particularly the lead candidate palazestrant, currently in two Phase 3 clinical trials, signaling strong developmental progress.
- Focus on transformative therapies for breast cancer, positioning Olema as a key player in an important and growing market.
Potential Negatives
- Participation in investor conferences may suggest the company is seeking to address investor concerns or lack of confidence regarding its current standing and pipeline progress.
- The focus on clinical-stage status may imply a prolonged timeline for potential revenue generation, which can be viewed negatively by investors seeking quicker returns.
- The mention of clinical trials, while necessary, also highlights ongoing uncertainty in outcomes, which may lead to volatility in stock performance.
FAQ
What is Olema Pharmaceuticals focused on?
Olema Pharmaceuticals focuses on the discovery, development, and commercialization of targeted therapies for breast cancer and other conditions.
When will Olema participate in investor conferences?
Olema will participate in investor conferences on May 26, June 3, and June 9, 2026.
Where can I find Olema's conference webcasts?
Live webcasts and recordings will be available in the Events and Presentations section of Olema’s investor relations website.
What is Olema's lead product candidate?
Olema's lead product candidate is palazestrant (OP-1250), an orally available estrogen receptor antagonist and selective estrogen receptor degrader.
Where is Olema Pharmaceuticals headquartered?
Olema Pharmaceuticals is headquartered in San Francisco, with operations also in Cambridge, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- IAN T CLARK has made 0 purchases and 3 sales selling 264,800 shares for an estimated $7,873,109.
- NASEEM ZOJWALLA (Chief Medical Officer) has made 0 purchases and 4 sales selling 269,509 shares for an estimated $7,530,147.
- DAVID C. MYLES (CH. DISCOV. & NON-CLIN DEV OFF) has made 0 purchases and 8 sales selling 161,000 shares for an estimated $4,660,772.
- SHANE WILLIAM CHARLES KOVACS (CH. OPERATING & FINANCIAL OFF.) has made 0 purchases and 2 sales selling 103,822 shares for an estimated $2,980,054.
- SHAWNTE MITCHELL (CHIEF LEGAL OFFICER) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $951,502.
- CYRUS HARMON has made 0 purchases and 3 sales selling 16,370 shares for an estimated $452,594.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OLMA Hedge Fund Activity
We have seen 125 institutional investors add shares of $OLMA stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,363,753 shares (+106.8%) to their portfolio in Q1 2026, for an estimated $79,973,557
- DEEP TRACK CAPITAL, LP removed 3,470,172 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $86,754,300
- JANUS HENDERSON GROUP PLC added 3,124,345 shares (+87.1%) to their portfolio in Q4 2025, for an estimated $78,108,625
- STATE STREET CORP added 2,053,432 shares (+109.0%) to their portfolio in Q1 2026, for an estimated $30,616,671
- SIREN, L.L.C. added 1,456,249 shares (+44.1%) to their portfolio in Q1 2026, for an estimated $21,712,672
- FRANKLIN RESOURCES INC removed 1,257,708 shares (-50.8%) from their portfolio in Q1 2026, for an estimated $18,752,426
- VESTAL POINT CAPITAL, LP removed 1,221,449 shares (-74.0%) from their portfolio in Q1 2026, for an estimated $18,211,804
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Piper Sandler issued a "Overweight" rating on 01/07/2026
- Citigroup issued a "Buy" rating on 12/12/2025
- Goldman Sachs issued a "Buy" rating on 11/21/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 9 analysts offer price targets for $OLMA in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Brad Canino from Guggenheim set a target price of $35.0 on 05/13/2026
- Dennis Ding from Jefferies set a target price of $40.0 on 03/19/2026
- Richard Law from Goldman Sachs set a target price of $27.0 on 03/18/2026
- Anupam Rama from JP Morgan set a target price of $58.0 on 03/18/2026
- Yigal Nochomovitz from Citigroup set a target price of $62.0 on 03/17/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $38.0 on 03/09/2026
- Laura Prendergast from Stifel set a target price of $48.0 on 02/11/2026
Full Release
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
TD Cowen 7
th
Annual Oncology Innovation Summit
Date and Time: May 26, 2026 at 12:30 p.m. ET
Format: Fireside Chat
Location: Virtual
Jefferies Global Healthcare Conference
Date and Time: June 3, 2026 at 8:45 a.m. ET
Format: Fireside Chat
Location: New York, NY
Goldman Sachs 47
th
Annual Global Healthcare Conference
Date and Time: June 9, 2026 at 3:20 p.m. ET
Format: Fireside Chat
Location: Miami, FL
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com .
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
